Freelite is a major breakthrough for the detection and monitoring of Multiple Myeloma (MM) and other B-cell dyscrasia.
Significant clinical evidence indicates the benefit of serum free light chain assays in:
1) Initial screening for monoclonal gammopathies
2) Identifying AL amyloidosis and Nonsecretory MM patients missed by conventional electrophoretic methods
3) As a prognostic indicator for progression in myeloma
4) For risk stratification of MGUS patients and rapid evaluation of treatment efficacy.
Freelite assays were developed by Binding Site to measure free lambda and free kappa immunoglobulin light chains.
Binding Site expertise in the manufacture of antibodies line of Business guarantees a quantifiable, highly specific, automatable free light chain assay for serum.
Bob Lock - A monoclonal v polyclonal approach to FLC measurement
Guidelines for the utility of Freelite in detecting and monitoring plasma cell disorders:
International Myeloma Working Group guidelines for serum-free light chain analysis in multiple myeloma and related disorders
International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma